Alston & Bird LLP
Alston & Bird LLP filed a Q3 report for Biomerieux, Inc. on October 20, 2026, reporting $70,000 in lobbying income.
Lobbying for Biomerieux, Inc. · Global in vitro diagnostics company.
-
JANE LUCAS New on this filingPreviously held: Special Assistant to the President, White House Office of Legislative Affairs; Principal Deputy Director, IOS-Office of Health Reform, HHS; Legislative Director, U.S. Senator John Thune.
Discussions regarding tariff proposals.
Support for H.R.3164/S.2426, Ensuring Community Access to Pharmacist Services Act.
Issues regarding prevention of antimicrobial resistance and incentives for development of new antibiotics.
Issues regarding prevention of antimicrobial resistance and incentives for development of new antibiotics. Reform of Medicare clinical laboratory payment per Section 216 of Protecting Access to Medicare Act, Pub. L. No. 113-93, and H.R.5269/S.2761, The Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act. Reforming technical certification of in vitro diagnostic tests.
Issues regarding prevention of antimicrobial resistance and incentives for development of new antibiotics. Reform of Medicare clinical laboratory payment per Section 216 of Protecting Access to Medicare Act, Pub. L. No. 113-93, and H.R.5269/S.2761, The Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act. Reforming technical certification of in vitro diagnostic tests.
Issues regarding prevention of antimicrobial resistance and incentives for development of new antibiotics. Reform of Medicare clinical laboratory payment per Section 216 of Protecting Access to Medicare Act, Pub. L. No. 113-93, and H.R.5269/S.2761, The Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act. Support for H.R.3164/S.2426, Ensuring Community Access to Pharmacist Services Act.